{"id":62991,"date":"2026-04-13T19:35:18","date_gmt":"2026-04-13T11:35:18","guid":{"rendered":"https:\/\/flcube.com\/?p=62991"},"modified":"2026-04-13T19:35:19","modified_gmt":"2026-04-13T11:35:19","slug":"boehringer-ingelheim-and-biontech-launch-phase-ib-ii-trial-of-novel-t-cell-engager-and-bispecific-antibody-combo-for-es-sclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62991","title":{"rendered":"Boehringer Ingelheim and BioNTech Launch Phase Ib\/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC"},"content":{"rendered":"\n<p><strong>Boehringer Ingelheim<\/strong> and <strong>BioNTech SE<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BNTX:NASDAQ\">NASDAQ: BNTX<\/a>) have announced a clinical collaboration to evaluate a novel immune-oncology combination therapy for <strong>extensive-stage small cell lung cancer (ES-SCLC)<\/strong>, one of the most aggressive and difficult-to-treat solid tumors. The Phase Ib\/II trial will assess Boehringer Ingelheim\u2019s investigational <strong>DLL3\/CD3 T-cell engager<\/strong>, <strong>obrixtamig (BI 764532)<\/strong>, in combination with BioNTech\u2019s <strong>PD-L1\/VEGF-A bispecific antibody<\/strong>, <strong>pumitamig (BNT327\/BMS-986545)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-collaboration-framework\">Collaboration Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Boehringer Ingelheim &amp; BioNTech SE<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Extensive-Stage Small Cell Lung Cancer (ES-SCLC)<\/td><\/tr><tr><td><strong>Boehringer Asset<\/strong><\/td><td>Obrixtamig (BI 764532) &#8211; DLL3\/CD3 T-cell engager<\/td><\/tr><tr><td><strong>BioNTech Asset<\/strong><\/td><td>Pumitamig (BNT327\/BMS-986545) &#8211; PD-L1\/VEGF-A bispecific (co-developed with BMS)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase Ib\/II<\/td><\/tr><tr><td><strong>Regulatory Sponsor<\/strong><\/td><td>Boehringer Ingelheim<\/td><\/tr><tr><td><strong>Asset Rights<\/strong><\/td><td>Fully retained by each company; agreement is non-exclusive<\/td><\/tr><tr><td><strong>Patient Dosing Start<\/strong><\/td><td>Second half of 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-scientific-rationale-amp-mechanism\">Scientific Rationale &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-Pronged Attack:<\/strong> The combination leverages two distinct but complementary mechanisms. <strong>Obrixtamig<\/strong> directly recruits and activates the patient\u2019s own T-cells to kill tumor cells expressing <strong>DLL3<\/strong>, a target highly prevalent in SCLC. <strong>Pumitamig<\/strong> simultaneously blocks the <strong>PD-L1<\/strong> immune checkpoint pathway to prevent T-cell exhaustion and inhibits <strong>VEGF-A<\/strong> to normalize tumor vasculature, potentially improving T-cell infiltration into the tumor microenvironment.<\/li>\n\n\n\n<li><strong>Addressing Unmet Need:<\/strong> ES-SCLC has seen limited therapeutic advances in decades, with poor long-term survival rates. This novel combination aims to overcome the immunosuppressive nature of the disease and deliver a more potent anti-tumor response.<\/li>\n\n\n\n<li><strong>Strategic Non-Exclusivity:<\/strong> The non-exclusive nature of the deal allows both companies to explore their assets in other combinations, preserving maximum strategic flexibility while de-risking this specific development path.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-amp-competitive-landscape\">Market &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High-Stakes Indication:<\/strong> A successful therapy in ES-SCLC would represent a major breakthrough, capturing significant market share in a field dominated by generic chemotherapy and limited immunotherapy options.<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> For Boehringer Ingelheim, success would validate its <strong>T-cell engager platform<\/strong>. For BioNTech, it would demonstrate the utility of its bispecific antibody technology beyond its core mRNA focus.<\/li>\n\n\n\n<li><strong>BMS Partnership Context:<\/strong> Pumitamig is co-developed with <strong>Bristol Myers Squibb (BMS)<\/strong>, adding another layer of strategic interest to the trial\u2019s outcome, though BMS is not a direct party to this specific collaboration.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief describes a planned clinical trial. The safety and efficacy of the combination therapy are unproven. The trial is subject to regulatory approvals and may be delayed or terminated. There can be no assurance that the combination will demonstrate a favorable benefit-risk profile or receive marketing approval.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boehringer Ingelheim and BioNTech SE (NASDAQ: BNTX) have announced a clinical collaboration to evaluate a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[342,429,390,428,29,28,1124],"class_list":["post-62991","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","category-drug","tag-biontech","tag-bms","tag-boehringer-ingelheim","tag-bristol-myers-squibb","tag-combination-therapy","tag-multi-specific-antibodies","tag-nasdaq-bntx"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boehringer Ingelheim and BioNTech Launch Phase Ib\/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Boehringer Ingelheim and BioNTech SE (NASDAQ: BNTX) have announced a clinical collaboration to evaluate a novel immune-oncology combination therapy for extensive-stage small cell lung cancer (ES-SCLC), one of the most aggressive and difficult-to-treat solid tumors. The Phase Ib\/II trial will assess Boehringer Ingelheim\u2019s investigational DLL3\/CD3 T-cell engager, obrixtamig (BI 764532), in combination with BioNTech\u2019s PD-L1\/VEGF-A bispecific antibody, pumitamig (BNT327\/BMS-986545).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62991\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim and BioNTech Launch Phase Ib\/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC\" \/>\n<meta property=\"og:description\" content=\"Boehringer Ingelheim and BioNTech SE (NASDAQ: BNTX) have announced a clinical collaboration to evaluate a novel immune-oncology combination therapy for extensive-stage small cell lung cancer (ES-SCLC), one of the most aggressive and difficult-to-treat solid tumors. The Phase Ib\/II trial will assess Boehringer Ingelheim\u2019s investigational DLL3\/CD3 T-cell engager, obrixtamig (BI 764532), in combination with BioNTech\u2019s PD-L1\/VEGF-A bispecific antibody, pumitamig (BNT327\/BMS-986545).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62991\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-13T11:35:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-13T11:35:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62991#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62991\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boehringer Ingelheim and BioNTech Launch Phase Ib\\\/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC\",\"datePublished\":\"2026-04-13T11:35:18+00:00\",\"dateModified\":\"2026-04-13T11:35:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62991\"},\"wordCount\":419,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BioNTech\",\"BMS\",\"Boehringer Ingelheim\",\"Bristol-Myers Squibb\",\"Combination therapy\",\"Multi-specific antibodies\",\"NASDAQ: BNTX\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62991#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62991\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62991\",\"name\":\"Boehringer Ingelheim and BioNTech Launch Phase Ib\\\/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-13T11:35:18+00:00\",\"dateModified\":\"2026-04-13T11:35:19+00:00\",\"description\":\"Boehringer Ingelheim and BioNTech SE (NASDAQ: BNTX) have announced a clinical collaboration to evaluate a novel immune-oncology combination therapy for extensive-stage small cell lung cancer (ES-SCLC), one of the most aggressive and difficult-to-treat solid tumors. The Phase Ib\\\/II trial will assess Boehringer Ingelheim\u2019s investigational DLL3\\\/CD3 T-cell engager, obrixtamig (BI 764532), in combination with BioNTech\u2019s PD-L1\\\/VEGF-A bispecific antibody, pumitamig (BNT327\\\/BMS-986545).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62991#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62991\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62991#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim and BioNTech Launch Phase Ib\\\/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim and BioNTech Launch Phase Ib\/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Boehringer Ingelheim and BioNTech SE (NASDAQ: BNTX) have announced a clinical collaboration to evaluate a novel immune-oncology combination therapy for extensive-stage small cell lung cancer (ES-SCLC), one of the most aggressive and difficult-to-treat solid tumors. The Phase Ib\/II trial will assess Boehringer Ingelheim\u2019s investigational DLL3\/CD3 T-cell engager, obrixtamig (BI 764532), in combination with BioNTech\u2019s PD-L1\/VEGF-A bispecific antibody, pumitamig (BNT327\/BMS-986545).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62991","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim and BioNTech Launch Phase Ib\/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC","og_description":"Boehringer Ingelheim and BioNTech SE (NASDAQ: BNTX) have announced a clinical collaboration to evaluate a novel immune-oncology combination therapy for extensive-stage small cell lung cancer (ES-SCLC), one of the most aggressive and difficult-to-treat solid tumors. The Phase Ib\/II trial will assess Boehringer Ingelheim\u2019s investigational DLL3\/CD3 T-cell engager, obrixtamig (BI 764532), in combination with BioNTech\u2019s PD-L1\/VEGF-A bispecific antibody, pumitamig (BNT327\/BMS-986545).","og_url":"https:\/\/flcube.com\/?p=62991","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-13T11:35:18+00:00","article_modified_time":"2026-04-13T11:35:19+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62991#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62991"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boehringer Ingelheim and BioNTech Launch Phase Ib\/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC","datePublished":"2026-04-13T11:35:18+00:00","dateModified":"2026-04-13T11:35:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62991"},"wordCount":419,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BioNTech","BMS","Boehringer Ingelheim","Bristol-Myers Squibb","Combination therapy","Multi-specific antibodies","NASDAQ: BNTX"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62991#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62991","url":"https:\/\/flcube.com\/?p=62991","name":"Boehringer Ingelheim and BioNTech Launch Phase Ib\/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-13T11:35:18+00:00","dateModified":"2026-04-13T11:35:19+00:00","description":"Boehringer Ingelheim and BioNTech SE (NASDAQ: BNTX) have announced a clinical collaboration to evaluate a novel immune-oncology combination therapy for extensive-stage small cell lung cancer (ES-SCLC), one of the most aggressive and difficult-to-treat solid tumors. The Phase Ib\/II trial will assess Boehringer Ingelheim\u2019s investigational DLL3\/CD3 T-cell engager, obrixtamig (BI 764532), in combination with BioNTech\u2019s PD-L1\/VEGF-A bispecific antibody, pumitamig (BNT327\/BMS-986545).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62991#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62991"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62991#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim and BioNTech Launch Phase Ib\/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62991","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62991"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62991\/revisions"}],"predecessor-version":[{"id":62992,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62991\/revisions\/62992"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62991"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62991"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62991"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}